Mcmaster University

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

McMaster University's inhaled COVID-19 vaccine demonstrated safety and immunogenicity in a Phase 1 trial of 36 healthy adults, with results published in Nature Communications.

The 62nd European Renal Association Congress in Vienna will present seven late-breaking clinical trials addressing chronic kidney disease, dialysis patients, and glomerular disease developments.

Late-breaking results from the CLEAR OASIS 9 trial reveal that colchicine failed to reduce cardiovascular events after myocardial infarction despite lowering inflammatory markers.

Researchers have identified lariocidin, the first new class of antibiotics to reach the market in nearly 30 years, discovered in bacteria from backyard soil samples.

Canadian researchers at McMaster University have begun phase-2 clinical trials for AeroVax, an innovative inhaled COVID-19 vaccine that directly targets the lungs and upper airways where infection begins.

A comprehensive 12-year PURE study across 17 countries shows significant underutilization of secondary prevention medications for cardiovascular disease, with usage rates dropping to 31.3% in the final study visit.